tiprankstipranks
Trending News
More News >

Next Science Reports Q1 FY25 Sales Decline Amid FDA Compliance Efforts

Story Highlights
Next Science Reports Q1 FY25 Sales Decline Amid FDA Compliance Efforts

Confident Investing Starts Here:

Next Science Ltd ( (AU:NXS) ) has provided an announcement.

Next Science Limited reported a slight decline in product sales for the first quarter of FY25, with total sales of US$5.3 million, a 3% decrease from the prior corresponding period. Despite a significant increase in direct sales of XPERIENCE and BLASTX products, the overall sales were impacted by a decline in Durable Medical Equipment (DME) sales. The company maintained a strong gross margin of 84%, attributed to a favorable product mix. Additionally, Next Science addressed an FDA Warning Letter, ensuring that their products remain safe and effective for their intended uses, and continued to focus on achieving a positive cash flow position.

More about Next Science Ltd

Next Science Limited is a medical technology company focused on commercializing its proprietary XBIO suite of products aimed at reducing the impact of biofilm-based infections in human health.

YTD Price Performance: -28.57%

Average Trading Volume: 6,181

Technical Sentiment Signal: Buy

Current Market Cap: $18.69M

See more data about NXS stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App